• Vitaspring Biomedical posted a net loss of USD 774,922 for the year ended Jan. 31, 2025, narrowing from USD 1,118,562.
• Operating loss improved to USD 679,914 as operating expenses fell to USD 679,914 from USD 1,118,562.
• Recorded USD 95,008 in income tax expense tied to interest and penalties on historical fiscal 2022 income tax obligations.
• Reported no revenue for fiscal 2025, unchanged from fiscal 2024.
• Ended the year with a USD 4,029,306 working capital deficit; cash was USD 272, while current liabilities totaled USD 4,029,578.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vitaspring Biomedical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-001019), on June 08, 2026, and is solely responsible for the information contained therein.